ACCEL Lite: ACC.21 Late Breaker: The ATLANTIS Trial

$ACCEL Lite: Are Primary Prevention ICDs Still Valuable in NICM?: Current guidelines recommend implantable cardioverter-defibrillators (ICDs) in nonischemic cardiomyopathy (NICM) among patients with heart failure and ejection fraction ≤35%. Should this change? Should cardiac resynchronization therapy pacemakers be...$

ACCEL Lite: Impact of PCI on Outcomes in Patients With HF: Observational studies suggest a benefit with PCI in patients with HF, but randomized data comparing PCI versus medical therapy or PCI versus coronary artery bypass grafting on outcomes and myocardial recovery are lacking. In this interview, Roxana... by ACCEL Lite: Featured ACCEL Interviews on Exciting CV Research

13 min listen

ACCEL Lite: Innovations in Remote Patient Monitoring: What Can it Bring to My Practice?: Personalizing care in the digital world has always been a challenge because of administrative burden and interoperability issues. The future is already here and we have the chance to leverage remote patient monitoring properly to engage patients with... by ACCEL Lite: Featured ACCEL Interviews on Exciting CV Research

13 min listen

ACCEL Lite: In-Hospital Initiation of Sodium Glucose Cotransporter-2 Inhibitors for Heart Failure with Reduced Ejection Fraction: Failure to initiate an SGLT2i to an eligible HFrEF patient exposes the patient to higher risk of early post-discharge death and readmission, and the real risk that the medication never gets prescribed at all. In this interview, Stephen J. Greene, MD... by ACCEL Lite: Featured ACCEL Interviews on Exciting CV Research

13 min listen

ACCEL Lite: Hypercoagulability in a Nutshell: What Do I Need to Know?: In this interview, Andrea Natale, MD, FACC, and Gregory Piazza, MD, FACC, discuss what you need to know about hypercoagulability in a nutshell. For 20+ insider interviews like these every month with CME/MOC credit, subscribe to ACCEL at www.ACC.org/ACCEL. by ACCEL Lite: Featured ACCEL Interviews on Exciting CV Research

12 min listen

ACCEL Lite: Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL-Cholesterol: After a heart attack, levels of blood lipids such as low-density lipoprotein cholesterol (LDL-C) may influence the risk of further cardiovascular events. In this analysis, we determined that even when LDL-C levels are controlled with a statin,... by ACCEL Lite: Featured ACCEL Interviews on Exciting CV Research

10 min listen

ACCEL Lite: ESC Late Breaker: FIGARO-DKD: Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes: This study investigates the efficacy and safety of finerenone, compared with a placebo to reduce clinically important cardiovascular and kidney outcomes in patients with chronic kidney disease and type 2 diabetes when added to the standard of care,... by ACCEL Lite: Featured ACCEL Interviews on Exciting CV Research

14 min listen

ACCEL Lite: Omecamtiv Mecarbil and EF in the GALACTIC-HF Trial: In this interview, Michelle O’Donoghue, MD, FACC; John Teerlink, MD, FACC; and Jeffrey Hsu, MD, PhD, discuss the effect of ejection fraction on clinical outcomes in patients treated with omecamtiv mecarbil in the GALACTIC-HF trial. Like what you... by ACCEL Lite: Featured ACCEL Interviews on Exciting CV Research

13 min listen

$ACCEL Lite: Omecamtiv Mecarbil and EF in the GALACTIC-HF Trial: In this interview, Michelle O’Donoghue, MD, FACC; John Teerlink, MD, FACC; and Jeffrey Hsu, MD, PhD, discuss the effect of ejection fraction on clinical outcomes in patients treated with omecamtiv mecarbil in the GALACTIC-HF trial. Like what you...$

ACCEL Lite: Pacemaker Patients Undergoing MRI: Many patients will undergo magnetic resonance imaging (MRI) in their lifetimes. It is important to know that, in most cases, it is possible to perform these scans on patients with a pacemaker as long as appropriate precautions are taken. In this... by ACCEL Lite: Featured ACCEL Interviews on Exciting CV Research

13 min listen

ACCEL Lite: Strategies to Maximize Doses and Introduce New Medication: As HF therapy continues to evolve, barriers like medication cost and non-adherence may impede patient care. Pharmacists can overcome these barriers through collaborative practice agreements and patient and provider education. In this interview, Sean... by ACCEL Lite: Featured ACCEL Interviews on Exciting CV Research

11 min listen

ACCEL Lite: ESC Congress 2021 Late Breaker: IAMI: In this interview, Laxmi Mehta, MD, FACC, and Ole Frobert, MD, PhD, and discuss the ESC Congress 2021 late breaker IAMI. This study evaluates whether influenza vaccination improves outcomes in patients with recent MI. Influenza vaccine reduced the... by ACCEL Lite: Featured ACCEL Interviews on Exciting CV Research

10 min listen

ACCEL Lite: Late Breaker: DIAMOND trial: Patiromer For The Management Of Hyperkalemia In Subjects Receiving Renin-angiotensin-aldosterone System Inhibitor Medications For HFrEF: Heart failure patients are generally multi-morbid and at risk for hyperkalemia, which makes treatment with life-saving therapies like RAASi difficult and leads to compromised medical treatment and in turn poor outcomes. This trials showed that with... by ACCEL Lite: Featured ACCEL Interviews on Exciting CV Research

14 min listen

ACCEL Lite: What Should Optimal Medical Therapy Look Like Prior to Intervention?: It is important that patients with reduced heart function are treated with drugs that have been documented to prolong survival. In this interview, Finn Gustafsson, MD, PhD and Michelle Kittleson MD, FACC, along with Michael Mikolaj MD, MPH, FACC,... by ACCEL Lite: Featured ACCEL Interviews on Exciting CV Research

10 min listen

ACCEL Lite: ESC Late Breaker: MASTER DAPT: Dual Antiplatelet Therapy After Coronary Stenting in High Bleeding Risk Patients by ACCEL Lite: Featured ACCEL Interviews on Exciting CV Research

12 min listen